Inflammation-mediated obesity and insulin resistance as targets for nutraceuticals

Annals of the New York Academy of Sciences

Volumn 1229, Issue 1, 2011, Pages 140-146

  Kim, Myung Sunny ^a   Lee, Myeong Soo ^b   Kown, Dae Young ^a  

^a Korea Food Research Institute   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Inflammation; Metabolic disease; Nutraceuticals; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 GINGEROL; 6 SHOGAOL; CAPSAICIN; CURCUMIN; CYANIDIN 3 GLUCOSIDE; EPIGALLOCATECHIN GALLATE; FLAVONOID; NUTRACEUTICAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOL DERIVATIVE; PLANT MEDICINAL PRODUCT; POLYUNSATURATED FATTY ACID; RESVERATROL; STILBENE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITISIN A;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; GINGER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; METABOLIC DISORDER; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OBESITY; TEA;

ANIMALIA;

EID: 79960779324     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06098.x     Document Type: Article

References (80)

1. Schenk, S., M. Saberi & J.M. Olefsky 2008. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118: 2992-3002.
2. Stumvoll, M., B. J. Goldstein & T.W. van Haeften 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
3. Shoelson, S.E., J. Lee & A.B. Goldfine 2006. Inflammation and insulin resistance. J. Clin. Invest. 116: 1793-1801.
4. Weisberg, S.P. et al. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112: 1796-1808.
5. Xu, H. et al 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830.
6. Feuerer, M. et al 2009. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15: 930-939.
7. Nishimura, S. et al 2009. CD8 +effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 15: 914-920.
8. Winer, S. et al 2009. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15: 921-929.
9. Hotamisligil, G.S., N.S. Shargill & B.M. Spiegelman 1993. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87-91.
10. Sethi, J.K. & G.S. Hotamisligil 1999. The role of TNF α in adipocyte metabolism. Semin. Cell. Dev. Biol. 10: 19-29.
11. Hotamisligil, G.S. et al 1995. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
12. Kern, P.A. et al. (1995. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95: 2111-2119.
13. Saghizadeh, M., et al. 1996. The expression of TNF α by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97: 1111-1116.
14. Uysal, K.T. et al 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389: 610-614.
15. Aguirre, V. et al 2000. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J. Biol. Chem. 275: 9047-9054.
16. Hirosumi, J. et al 2002. A central role for JNK in obesity and insulin resistance. Nature 420: 333-336.
17. Yuan, M. et al. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293: 1673-1677.
18. Lee, J.Y. et al 2001. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276: 16683-16689.
19. Vallerie, S.N. & G.S. Hotamisligil 2010. The role of JNK proteins in metabolism. Sci. Transl. Med. 2: 60rv65.
20. Summers, S.A. 2006. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45: 42-72.
21. Forman, B.M. et al 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 83: 803-812.
22. Jiang, C., A.T. Ting & B. Seed 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
23. Marx, N. et al 1998. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytesin vitro. Am. J. Pathol. 153: 17-23.
24. Ricote, M. et al 1998. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 95: 7614-7619.
25. Ricote, M. et al 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82.
26. Hevener, A.L. et al 2007. Macrophage PPAR γ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117: 1658-1669.
27. Odegaard, J.I. et al 2007. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447: 1116-1120.
28. Suzawa, M. et al 2003. Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade. Nat. Cell. Biol. 5: 224-230.
29. Ghanim, H. et al 2004. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110: 1564-1571.
30. Mendall, M.A. et al 1997. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78: 273-277.
31. Nieman, D.C. et al 1999. Influence of obesity on immune function. J. Am. Diet. Assoc. 99: 294-299.
32. Woo, H.M. et al 2007. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci. 80: 926-931.
33. Wang, S.L. et al 2009. Curcumin, a potential inhibitor of up-regulation of TNF-α and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-κB and JNK pathway. Biomed. Environ. Sci. 22: 32-39.
34. Pendurthi, U.R. & L.V. Rao 2000. Suppression of transcription factor Egr-1 by curcumin. Thromb. Res. 97: 179-189.
35. Weisberg, S.P., R. Leibel & D.V. Tortoriello 2008. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149: 3549-3558.
36. Jain, S.K. et al 2009. Curcumin supplementation lowers TNF-α, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-α, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid. Redox. Signal. 11: 241-249.
37. Kim, C.S. et al 2003. Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. Cell. Signal. 15: 299-306.
38. Manjunatha, H. & K. Srinivasan 2006. Protective effect of dietary curcumin and capsaicin on induced oxidation of low-density lipoprotein, iron-induced hepatotoxicity and carrageenan-induced inflammation in experimental rats. FEBS J. 273: 4528-4537.
39. Park, J.Y. et al 2004. Capsaicin inhibits the production of tumor necrosis factor α by LPS-stimulated murine macrophages, RAW 264.7: a PPARγ ligand-like action as a novel mechanism. FEBS Lett. 572: 266-270.
40. Kang, J.H. et al 2007. Capsaicin, a spicy component of hot peppers, modulates adipokine gene expression and protein release from obese-mouse adipose tissues and isolated adipocytes, and suppresses the inflammatory responses of adipose tissue macrophages. FEBS Lett. 581: 4389-4396.
41. Shin, K.O. & T. Moritani 2007. Alterations of autonomic nervous activity and energy metabolism by capsaicin ingestion during aerobic exercise in healthy men. J. Nutr. Sci. Vitaminol. 53: 124-132.
42. Suri, A. & A. Szallasi 2008. The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol. Sci. 29: 29-36.
43. Joo, J.I. et al 2010. Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J. Proteome Res. 9: 2977-2987.
44. Kim, D.H. et al 2010. Differential expression of skeletal muscle proteins in high-fat diet-fed rats in response to capsaicin feeding. Proteomics 10: 2870-2881.
45. Singh, S., K. Natarajan & B.B. Aggarwal 1996. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-κ B activation by diverse agents. J. Immunol. 157: 4412-4420.
46. Aggarwal, B.B. 2010. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 30: 173-199.
47. Shi, H. et al 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116: 3015-3025.
48. Batetta, B. et al 2009. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J. Nutr. 139: 1495-1501.
49. Lee, J.Y. et al 2003. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J. Lipid Res. 44: 479-486.
50. Oh, D.Y. et al 2010. GPR120 is an ω-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698.
51. Huber, J. et al 2007. Prevention of high-fat diet-induced adipose tissue remodeling in obese diabetic mice by n-3 polyunsaturated fatty acids. Int. J. Obes. 31: 1004-1013.
52. Todoric, J. et al 2006. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49: 2109-2119.
53. Meijerink, J. et al 2011. The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new link between fish oil and inflammation. Br. J. Nutr. Feb. 4: 1-10 [Epub ahead of print]
54. Baur, J.A. & D.A. Sinclair 2006. Therapeutic potential of resveratrol: thein vivoevidence. Nat. Rev. Drug Discov. 5: 493-506.
55. Fremont, L. 2000. Biological effects of resveratrol. Life Sci. 66: 663-673.
56. Jang, M. et al 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
57. Pillarisetti, S. 2008. A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases. Recent Pat. Cardiovasc. Drug Discov. 3: 156-164.
58. Kim, S. et al 2011. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochemical Pharmacol. 81: 1343-1351.
59. Rayalam, S. et al 2008. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother. Res. 22: 1367-1371.
60. Zhu, J. et al 2008. Anti-inflammatory effect of resveratrol on TNF-α-induced MCP-1 expression in adipocytes. Biochem. Biophys. Res. Commun. 369: 471-477.
61. Kumar, A. & S.S. Sharma 2010. NF-κB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun. 394: 360-365.
62. Losso, J.N., R.E. Truax & G. Richard 2010. Trans-resveratrol inhibits hyperglycemia-induced inflammation and connexin downregulation in retinal pigment epithelial cells. J. Agric. Food Chem. 58: 8246-8252.
63. Szewczuk, L.M. et al 2004. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem. 279: 22727-22737.
64. Zhang, H. et al 2009. Resveratrol improves endothelial function: role of TNFα and vascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 29: 1164-1171.
65. Mi Jeong, S. et al 2009. Vitisin A suppresses LPS-induced NO production by inhibiting ERK, p38, and NF-κB activation in RAW 264.7 cells. Int. Immunopharmacol. 9: 319-323.
66. Huang, K.S., M. Lin & G.F. Cheng 2001. Anti-inflammatory tetramers of resveratrol from the roots ofVitis amurensisand the conformations of the seven-membered ring in some oligostilbenes. Phytochemistry 58: 357-362.
67. Kim, S.H. et al 2008. Vitisin A inhibits adipocyte differentiation through cell cycle arrest in 3T3-L1 cells. Biochem. Biophys. Res. Commun. 372: 108-113.
68. Koo, M. et al 2008. 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitory effect ofVitis vinifera. Fitoterapia 79: 204-206.
69. Levy, A.S. et al 2006. 6-Shogaol reduced chronic inflammatory response in the knees of rats treated with complete Freund's adjuvant. BMC Pharmacol. 6: 12.
70. Ojewole, J.A. 2006. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract ofZingiber officinale (Roscoe) rhizomes(Zingiberaceae) in mice and rats. Phytother. Res. 20: 764-772.
71. Sekiya, K., A. Ohtani & S. Kusano 2004. Enhancement of insulin sensitivity in adipocytes by ginger. Biofactors 22: 153-156.
72. Isa, Y. et al 2008. 6-Shogaol and 6-gingerol, the pungent of ginger, inhibit TNF-α mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 373: 429-434.
73. Kim, S.O. et al 2005. [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-κB in phorbol ester-stimulated mouse skin. Oncogene 24: 2558-2567.
74. Garcia-Lafuente, A. et al 2009. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm. Res. 58: 537-552.
75. Tsuda, T. 2008. Regulation of adipocyte function by anthocyanins: possibility of preventing the metabolic syndrome. J. Agric. Food Chem. 56: 642-646.
76. Tsuda, T. et al 2003. Dietary cyanidin 3-O-β-D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. J. Nutr. 133: 2125-2130.
77. Sasaki, R. et al 2007. Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice. Biochem. Pharmacol. 74: 1619-1627.
78. Bose, M. et al 2008. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J. Nutr. 138: 1677-1683.
79. Imai, K. & K. Nakachi 1995. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Br. Med. J. 310: 693-696.
80. Steptoe, A. et al 2007. The effects of chronic tea intake on platelet activation and inflammation: a double-blind placebo controlled trial. Atherosclerosis 193: 277-282.